|星空彩票电脑版
%A HOU Wen-shu，ZHANG Li %T
Research Progress on Pharmacological Action and Dosage Form of Tanshinone II A on Cardiovascular System%0 Journal Article %D 2016 %J ACTA NEUROPHARMACOLOGICA %R 10.3969/j.issn.2095-1396.2016.04.004 %P 24-30 %V 6 %N 4 %U {http://actanp.hebeinu.edu.cn/CN/abstract/article_324.shtml} %8 2016-08-26 %X Tanshinone Ⅱ A is not only a kind of important fat-soluble extract which comes from Labiatae Salvia miltiorrhiza but also a kind of the most effective pharmacological active ingredients. So many experiments and clinical studies have shown that tanshinone Ⅱ A can prevent or attenuate the progress of multiple diseases including cardiovascular disease，cancer，neonatal hypoxic ischemic encephalopathy，liver fibrosis and neurodegenerative disease. With aging of population’s development，cardiovascular disease has become a common disease which threatens human health ranking fi rst of all causes of death. Tanshinone Ⅱ A has the effects of anti-atherosclerosis，anti-myocardial ischemia，anti-arrhythmic，repair of vascular endothelial cells and improvement of coronary blood circulation in cardiovascular system，however，tanshinone Ⅱ A is a fat-soluble component with the disadvantages of poor oral absorption and low bioavailability. Therefore，in order to improve the present situation of tanshinone Ⅱ A ，new dosage forms of tanshinone Ⅱ A should be prepared，such as injectable microemulsions，micro pill，solid dispersions，liposomes，nanoparticles，etc. Therefore，this article summarizes the domestic and international research situation. The results showed the development of new dosage forms made tanshinone Ⅱ A play a greater medical value in the treatment of cardiovascular diseases，providing theoretical guidance for further research.